In Development
Voclosporin a next generation calcineurin inhibitor, has successfully completed a Phase 2b kidney transplant (PROMISE) trial and a Canadian Phase 3 trial for the treatment of moderate to severe psoriasis. An extension to the PROMISE trial and a combined European/Canadian Phase 3 psoriasis (ESSENCE) trial for the treatment of moderate to severe psoriasis are ongoing.
Our partner, Lux Biosciences, initiated pivotal trials of voclosporin in uveitis in February, 2007. The data, announced in March 2009 showed a positive effect on ocular inflammation and a safety profile consistent with the expected use in uveitis. In addition to the uveitis trials, Lux Biosciences has also commenced a Phase 1 trial using the voclosporin ophthalmic solution as a candidate for dry eye syndrome.
Voclosporin has also entered First-in-Man trials as the drug utilized in the CINATRA TM Drug Coated Coronary Stent system developed by the Company's partner, Atrium Medical Corporation.
TAFA93 is a novel prodrug of the mTOR inhibitor Rapamycin. TAFA93 has been designed to attenuate the unfavorable pharmacokinetics and side effects of Rapamycin which presently limit its broader use. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, in the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease. TAFA93 has successfully completed Phase 1 clinical trials.
Immunosuppressive Drug Market Potential
